Competition Warning for Eight NHS Trusts

Eight NHS hospital trusts have provided guarantees to the Office of Fair Trading (OFT) that they will stop exchanging commercially-sensitive information about their Private Patient Unit (PPU) prices, and ensure that they conform to competition law. The Office of Fair Trading confronted members of the Southern Region Private Healthcare Association (SPHA) earlier this year, after

Continue Reading

AstraZeneca Teams With Regulus’ MicroRNA Therapeutics

AstraZeneca has announced that they have entered into a strategic partnership with US biopharmaceutical group Regulus Therapeutics to discover, develop, and commercialise microRNA therapeutics. The Anglo-Swedish drug giant has agreed to pay $28 million, which includes an equity investment and an upfront fee, so they can exclusively work with Regulus on the development of three

Continue Reading

Elan Separates Discovery Activities into Neotope

Elan today has announced that they have decided to spin off of their discovery science and Neotope Biosciences divisions into a separate business entity “to create two independent, highly focused, public companies.” After the separation, Elan will hold three key assets: the multiple sclerosis blockbuster Tysabri and its other potential indications; ELND005, a Phase II/Phase

Continue Reading

UK Branded Drug Pricing Arrangements from 2014

The UK department of health and the ABPI (Association of the British Pharmaceutical Industry) have set the groundwork for discussions over the new pricing structure for medicines in the UK, which will come into force in 2014 after the current Pharmaceutical Price Regulation Scheme (PPRS) scheme finishes. In a joint statement released Friday they confirmed

Continue Reading

Teva Profits Increased by US Generic Sales

Teva Pharmaceutical Industries announced solid financials for the second quarter of 2012, improved by sales of their multiple sclerosis drug Copaxone, sturdy generics growth in the US and the contribution of Cephalon’s products. Net income increased by 50% to $863 billion, while sales grew 19% to $4.99 billion.  Turnover climbed by 28% in America to

Continue Reading

GPs Account for Under Half of CCG Board Members

GPs account for less than half of the available leadership roles in the emerging clinical commissioning groups (CCG) across England, igniting concerns that doctors are being pushed aside from the decision-making procedure on which services to offer patients. According to an enquiry by Pulse magazine, replies from 100 different clinical commissioning groups exposed that only

Continue Reading

Vifor and Grünenthal ‘Named and Shamed’ for Breaking ABPI Code

Pharmaceutical companies Grünenthal and Vifor have been ‘named and shamed’ in numerous publications for breaking the Association of the British Pharmaceutical Industry’s (ABPI’s) Code of Practice. Grünenthal has been criticised for the way in which their team of health economic liaison managers drove interest in and awareness of their unlicensed pain reliever treatment, tapentadol. The

Continue Reading

Research Study Reveals Medication Warning Labels Require Overhaul

Numerous patients appear to overlook prescription drug warning labels with directions that are vital for safe and effective use, a research study by scientists at Michigan State University and a Kansas State University researcher have found. Patients, predominantly older ones, frequently ignore prescription advice labels partly due to the labels failing to capture their attention,

Continue Reading